Does OLAPARIB Cause Neoplasm malignant? 133 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 133 reports of Neoplasm malignant have been filed in association with OLAPARIB (Lynparza). This represents 0.7% of all adverse event reports for OLAPARIB.
133
Reports of Neoplasm malignant with OLAPARIB
0.7%
of all OLAPARIB reports
20
Deaths
12
Hospitalizations
How Dangerous Is Neoplasm malignant From OLAPARIB?
Of the 133 reports, 20 (15.0%) resulted in death, 12 (9.0%) required hospitalization, and 6 (4.5%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 133 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which OLAPARIB Alternatives Have Lower Neoplasm malignant Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL